Registry status of Innovent's mazdutide 9 mg obesity trial changes to unknown

The registry entry for Innovent Biologics' Phase 3 study of mazdutide 9 mg in Chinese adults with obesity has changed from 'active, not recruiting' to 'unknown' ^[1]. The study is GLORY-2 (NCT06164873), the trial that reported up to 20.1% average weight loss at 60 weeks in people without type 2 diabetes ^[2].

The change was recorded in late August 2026 ^[1].

What the status change does and does not mean

The record is kept on ClinicalTrials.gov, which shows only the current value of a field and keeps no public history of what it said before. A log that snapshots the registry six times a day and compares each snapshot with the previous one recorded the old value alongside the new one ^[1]. Without that kind of monitoring, a status change of this sort is invisible the day after it happens ^[1].

An 'unknown' status means the sponsor has not verified the record within the registry's expected window ^[1]. It is an administrative signal about the accuracy of the listing, not a reported clinical finding: the entry does not say the trial stopped, that any participant was harmed, or that results changed.

What the trial reported

GLORY-2 enrolled 462 Chinese adults with obesity, defined as a body mass index of at least 30 kg/m², and randomized them 2:1 to mazdutide 9 mg or placebo for a 60-week double-blind treatment period. Mean starting weight was 94.0 kg and mean starting BMI was 34.3; 16% of participants had type 2 diabetes ^[2].

At week 60, the mazdutide 9 mg group had a mean weight reduction of 18.55%, compared with 3.02% for placebo, and 44.0% of participants on the drug lost 20% or more of their body weight, versus 2.6% on placebo. Among participants without type 2 diabetes, mean weight reduction was 20.08% for mazdutide versus 2.81% for placebo, and 48.7% lost at least 20%, versus 3.1% ^[2].

In a subset with baseline liver fat of 10% or more, average liver fat fell 71.9% on mazdutide and rose 5.1% on placebo. Discontinuation because of adverse events was 2.9% in the mazdutide group and 0% in the placebo group ^[2].

Mazdutide is a dual glucagon/GLP-1 receptor agonist licensed to Innovent by Eli Lilly for development and potential commercialization in China ^[2]. It is not semaglutide or tirzepatide, and it is not a combination of the two. Innovent said in November 2025 that it planned to submit an application for mazdutide 9 mg for weight management to China's drug regulator in the near term, and that mazdutide already holds two approvals in China, for chronic weight management and for blood sugar control in type 2 diabetes ^[2].

Why it matters for patients

Mazdutide is not available in the United States, and no US filing or approval has been disclosed ^[2]. For American patients, the practical effect of this registry change is close to zero: it does not add a treatment option, remove one, or change any reported result. Someone tracking the drug's development, however, now sees an entry that reads 'unknown' instead of 'active, not recruiting' ^[1].

The results reported in November 2025 remain the most recent clinical information on the 9 mg dose ^[2]. The registry entry itself is not a source of safety or efficacy information, and the change does not indicate that the trial's findings are in question.

What happens next

Innovent said the 9 mg application would go to China's Center for Drug Evaluation in the near term and described the timing only as the near future; no submission date has been disclosed, and whether that filing has happened has not been reported ^[2]. The company also listed GLORY-3, comparing mazdutide with semaglutide 2.4 mg in Chinese adults with overweight or obesity and fatty liver disease, and GLORY-OSA in Chinese adults with obstructive sleep apnea and obesity, as still ongoing ^[2].

Whether the registry record for the 9 mg obesity trial is updated, restored to 'active, not recruiting,' or left as 'unknown' has not been reported ^[1].